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Abstract
Treatment of advanced heart failure with implantable LVADs is increasing, driven by profound unmet patient
need despite potential serious complications: bleeding, infection, and thrombus. The experimental objective
was to develop a sensitive imaging approach to assess early thrombus accumulation in LVADs under
operational high flow and high shear rates.
Methods: A monomeric bifunctional ligand with a fibrin-specific peptide, a short spacer, and 99mTc chelating
amino acid sequence (F1A) was developed and compared to its tetrameric PEG analogue (F4A).
Results: 99mTc attenuation by LVAD titanium (1 mm) was 23%. 99mTc-F1A affinity to fibrin was Kd ~10 µM,
whereas, the bound 99mTc-F4A probe was not displaced by F1A (120,000:1). Human plasma interfered with
99mTc-F1A binding to fibrin clot (p<0.05) in vitro, whereas, 99mTc-F4A targeting was unaffected. The
pharmacokinetic half-life of 99mTc-F4A was 28% faster (124±41 min) than 99mTc-F1A (176±26 min) with both
being bioeliminated through the urinary system with negligible liver or spleen biodistribution. In mice with
carotid thrombus, 99mTc-F4A binding to the injured carotid was much greater (16.3±3.3 %ID/g, p=0.01) than
that measured with an irrelevant negative control, 99mTc-I4A (3.4±1.6 %ID/g). In an LVAD mock flow-loop (1:1,
PBS:human plasma:heparin) operating at maximal flow rate, 99mTc-F4A bound well to phantom clots in 2 min
(p<0.05), whereas 99mTc-F1A had negligible targeting. Excised LVADs from patients undergoing pump exchange
or heart transplant were rewired, studied in the mock flow loop, and found to have spatially variable fibrin
accumulations in the inlet and outlet cannulas and bearings.
Conclusions: 99mTc-F4A is a high-avidity prototype probe for characterizing thrombus in LVADs that is
anticipated to help optimize anticoagulation, reduce thromboembolic events, and minimize pump exchange.
Key words: LVAD, thrombosis, nuclear imaging, fibrin, technetium

Introduction
Heart failure (HF) annually affects over five
million Americans of all ages, both sexes, and all races
[1]. Patients with refractory Stage D heart failure have
limited options: 1) heart transplantation, but only
3,000 donor hearts are available annually; 2)
mechanical circulatory support, such as a left
ventricular assist device (LVAD); or 3) hospice care
with death typically transpiring within months [2-5].
While LVAD placement offers benefits to many

patients with severe HF, their successful clinical use
requires prevention and management of well-known
complications: 1) gastrointestinal bleeding (GIB) due
to platelet dysfunction secondary to the high shear
effects [6], 2) bacterial infections along the
percutaneous driveline, 3) intra-pump thrombus and
stroke [7-9]. In terms of hospital readmissions,
bleeding, infection, and thrombus were 30%, 22%, and
14%, respectively, in one retrospective study [8].
http://www.thno.org
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Prevention of GI bleeding through refinement and
shifting of the warfarin International Normalized
Ratio (INR) guideline ranges and manipulation of the
timing and extent of antiplatelet and anticoagulation
regimen used has had anecdotal but no generalized
clinical success [10-12]. Multicenter results indicated
unexpectedly that lowering the INR range to reduce
bleeding events tripled the incidence of pump
thrombotic complications [12, 13]. Efforts to manage
anticoagulation and minimize bleeding events are
complicated by the lack of a sensitive, direct
biomarker to characterize LVAD thrombus
accumulation or rule it out.
The sensitive and specific diagnosis of pump
thrombus remains a clinical dilemma [14-18].
Currently, pump thrombus is suspected based on
indirect evidence of increased erythrocyte hemolysis,
such as elevated serum lactic dehydrogenase levels

(LDH) and decreased serum haptoglobin, changes in
LVAD power consumption, or by suggestive
echocardiographic signs, such as new aortic valve
opening or the lack of left ventricular (LV)
decompression
with
dynamic
testing
[19].
Echocardiographic ramp studies offer early effective
LV optimization of LVAD pump speeds and late
pump thrombosis detection in patients suspected of
clinical LVAD malfunction [20]. In rare cases, a large
pump thrombus may be detected by computed
tomography (CT) angiography [21].
Thrombus imaging has a rich history dating back
to the mid 1970s and continuing to the present [22].
Both platelets and fibrin have been the dominant
thrombus targets studied, but LVAD thrombus is
typically an acellular fibrin accretion [23]. Acute
vascular thrombi are readily imaged with virtually all
clot-specific contrast agents, but aged thrombi greater
than 48 h to 72 h are poorly targeted
[22]. Thrombus homing is further
degraded by anti-coagulation use,
which may be clinically necessitated
to prevent or treat suspected
thrombosis [22]. LVAD thrombus
develops
over
time
despite
concurrent anticoagulation with
warfarin and aspirin [24, 25].
Direct
diagnosis
and
quantification of pump thrombus
with noninvasive imaging is further
complicated by the LVAD titanium
housing, which precludes the use of
magnetic resonance imaging (MRI),
CT, or ultrasound and favors a
nuclear medicine approach. Indeed,
the high-shear and high blood flow
conditions created by an LVAD, such
as the HeartMate II (HMII,
Abbott-Thoratec,
Lake
Bluff,
Illinois), spinning at 8,800-10,000
RPM, necessitate a probe with high
molecular specificity and extreme
binding avidity. Further, radioactive
background in blood passing
through the pump or accumulating
in surrounding organs must be
minimized to afford effective
signal-to-noise.
The objective of this project was
Figure 1. A Diagrammatic representation of a HeartMate II (HMII) left ventricular assist device (LVAD). Blood
to evaluate a sensitive and specific
(orange arrow) is drawn into the pump through a cannula from the ventricular apex, flows by the stator through
anti-fibrin probe prototype concept
the turbine and returns to systemic circulation through the outlet cannula into the aorta. The pump is powered
through an externalized driveline cable on the outlet side of the LVAD. B Small residual LVAD thrombus on the
for targeting thrombus in the
inlet stator and around the bearing (C) from a patient admitted with elevated lactate dehydrogenase (LDH)
anticoagulated high-flow, high shear
(1300's) after symptomatic hemorrhagic/embolic stroke due to a suspected pump thrombus. White arrows point
to residual thrombus. HMII image is copyright protected by Thoratec, Inc and used with permission.
environment of LVADs. Monomeric
and tetrameric 99mTc probes were
http://www.thno.org
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evaluated and compared in vitro for fibrin clot
binding signal in PBS, with and without a strong
amino acid tridentate ligand (cysteine), and plasma.
Pharmacokinetic and biodistribution studies of the
monomeric and tetrameric nuclear probes were
delineated along with selective in vivo targeting to
carotid thrombus in mice. The relative binding of the
monomeric and tetrameric probes to acute fibrin clots
were compared within a Heartmate II mock loop
flowing heparinized plasma:PBS at approximately 6
L/min. 99mTc attenuation through titanium, as used in
the pump housing, was characterized. LVADs excised
from patients undergoing heart transplant or LVAD
exchange were rewired and exposed to the tetrameric
fibrin probe in the mock flow-loop system under near
maximal flow conditions followed by high-resolution
NanoSPECT imaging assessments to assess inherent
accumulation of intra-pump thrombus. The
overarching result of this proof-of-concept study
suggests that direct imaging assessments of LVAD
thrombus accumulation, or lack thereof, could
improve and individualize patient management
decisions with the potential to minimize thrombotic
events, decrease hemorrhaging, and reduce surgical
pump exchanges.

Materials and Methods
Solid phase synthesis of monomeric (F1A) and
tetrameric (F4A) fibrin probes
Monomeric unit (F1A) is a bifunctional entity
comprising a fibrin-specific natural peptide analogue
(QIWCLGYPCEWQ) [26] interconnected through a
diethylene
glycol
(DEG)
spacer
to
a
technetium-chelating
amino
acid
sequence
(HHE-DEG) (Figure 2A). PEG2000 tetramer was used to
couple four F1A monomers to form F4A (Figure 2B).
Briefly, peptide precursors were synthesized with a
CS136 peptide synthesizer at a 0.2 mmol scale.
Standard solid phase Fmoc peptide synthesis was
used [27]. F1A was synthesized with high purity
(>95%). The final product was analyzed by HPLC and
ESI-TOF mass spectrometry: ESI-TOF (positive
mode): m/z [C94H126N24O26S2 + 2H]+ Calcd.
1036.4 Da.; Obsd. 1036.3 Da. To obtain the
tetramer, the
side-chain
protecting
group,
4-{N-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-me
thylbutyl]-amino}benzyl (Dmab) was selectively
removed from glutamate and coupled with the
4-arm-PEG amine (PSB-431, 2K, Creative PEGWorks,
Chapel Hill, NC). F4A was purified with size
exclusion chromatography (Zeba Desalt Spin
Column, 2 mL, ThermoScientific) using 10% acetic
acid in water followed by three deionized water
washes. The overall yield of F4A was <10%. MALDI
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characterization of the product revealed an array of
molecular weights arising from an unexpectedly high
polydispersity of the tetrameric PEG core. (See
Supplementary Material).
99mTc

labeling of F1A and F4A

F1A and F4A were radiolabeled to the HHE
sequence with 99mTc for gamma imaging [28]. This
was accomplished by adding Na99mTcO4 (~9 mCi; 1.0
mL) in saline to an IsoLink vial (Center for
Radiopharmaceutical Sciences of PSI, ETH and USZ,
Paul Scherrer Institute, Switzerland). 99mTc-F1A
optimally binds one 99mTc nuclide and the 99mTc-F4A
chelates up to four metal atoms, one on each arm
(Figure 2B). Given the rapid radioactive decay of 99mTc
to 99Tc as well as the elution status of the
molybdenum generator yield, typical specific
activities of the 99mTc-F1A and 99mTc-F4A probes were
40 mCi/µmol with 90% to 95% radiochemical purity
based on radio-thin layer chromatography (0.1 M
NaAc pH 5.18:MeOH:H2O = 20:100:200).

Acellular fibrin clot assays
Acellular fibrin clots were used: 1) to
characterize the binding affinity of 99mTc-F1A and the
relative avidity of 99mTc-F4A, 2) to assess the stability
of 99mTc chelation, and 3) to evaluate the matrix effect
of plasma on the probe binding to fibrin clots.
Uniform clots were produced by quickly admixing
100 µL of fresh frozen human plasma with 3 U
thrombin and calcium chloride (Sigma-Aldrich
Chemical, St. Louis, MO). The mixture was pipetted
into uniform cylindrical plastic tubes. Once formed,
clots were washed repeatedly in 0.1 M PBS buffer (pH
7.0) then stored at 4 °C in same until use.

Fibrin binding affinity
99mTc-F1A

(20 µCi) was incubated with the clot
samples at 37 °C for 30 min with 1, 5, 10, 15, 25, and 30
µg cold monomer supplemented with 0.1 M PBS pH
7.4 to bring each test volume total to 0.5 mL. The fibrin
clots were separated from unbound radioactivity by
repeated centrifugation and washing then were
counted in a calibrated well counter (Wizard 3, Perkin
Elmer, Waltham, MA). Results, adjusted for decay,
were used to estimate the dissociation constant (Kd)
using
the
Hill
slope
model
(h),
Y=Bmax*Xh/(Kdh + Xh) (MatLab, Natick, MA) where
Kd is the ligand concentration that binds to half the
receptor sites at equilibrium, Bmax is the maximum
number of binding sites, X is the radioligand
concentration and h is the Hill slope, an estimate of
binding cooperativity. Total fibrin concentration was
estimated from plasma fibrinogen to be 0.735 nmol
per clot. 99mTc-F4A (20 µCi) was incubated with the
http://www.thno.org
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clot samples at 37 °C in the presence of unlabeled F1A,
which was titrated to a 120,000:1 excess relative to
99mTc-F4A, to assess the relative avidity of the
tetrameric probe.
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Assessment of 99mTc-F1A and 99mTc-F4A
radiolabel stability and plasma interference
Radiolabeled F1A and F4A were bound to clots
in the presence of marked excess cysteine to evaluate
the stability of the 99mTc label in triplicate [29].
99mTc-F1A or 99mTc-F4A (20 µCi) supplemented with
0.1 M PBS pH 7.4 (total volume of 0.5 mL) were
incubated with fibrin clot samples at 37 °C for 30 min.

Figure 2. A 99mTc carbonyl aqua-ion and the complex formed with HH-peptide. B 99mTc-F1A bi-functional monomer depicting the cyclic homing sequence, short spacer, and
99mTc-chelating site depicting 99mTc carbonyl coupling. C 99mTc-F4A tetramer created by the balanced cross-linking of the four F1A monomers with tetrameric PEG arms (shown
with one example of 99mTc on one of the four arms for clarity). PEG: polyethylene glycol. Bold arrows point to 99mTc carbonyl coupling in example illustrations.

http://www.thno.org
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Similarly, the 0.1 M PBS buffer diluted 50% with fresh
frozen human plasma (total volume of 0.5 mL) was
used to assess potential plasma matrix interference on
radiolabeled peptide binding in triplicate. In both
instances, fibrin clots were separated from unbound
radioactivity by repeated centrifugation, were
washed, then counted in a calibrated well counter
(Wizard 3, Perkin-Elmer).

Gamma signal attenuation from titanium
LVAD housing
Na99mTcO4 was serially diluted into plastic
snap-cap vials from 20 µCi to 0.5 µCi and radioactivity
was evaluated using the Multispectral FX multimodal
imaging system (Bruker-Biospin, Billerica, MA) with
the isotope phosphor screen for planar scintigraphy
using a 1.0 min acquisition time. Samples were
imaged before and after placement of a 1 mm titanium
sheet provided by Thoratec Corp., which
corresponded to the titanium metal used to form the
LVAD HMII housing.

Pharmacokinetics (PK) and biodistribution
(BD) of 99mTc-F1A and 99mTc-F4A in mice
All animal research was conducted under a
protocol approved by the Washington University
Animal Studies Committee.
The pharmacokinetics of 99mTc-F1A and
99mTc-F4A were studied in triplicate in mice (male,
Harlan, C57BL/6, 4-6 wks). Mice were anesthetized
with ketamine (85 mg/kg) / xylazine (10 mg/kg) and
maintained with 1-2% isoflurane through a nosecone.
99mTc-F1A or 99mTc-F4A (16-30 µCi) were injected via
tail vein and serial blood samples were obtained at 0,
2, 5, 10, 15, 20, 30, 60, 120, and 180 min via an
indwelling jugular catheter. Blood samples were
timed, weighed, and counted with a calibrated
gamma counter (Wizard 3, Perkin-Elmer). The data
were adjusted for decay relative to the time of
counting and were fit to bi-exponential models using
MatLab (Natick, MA). After 180 min animals were
euthanized; tissue and fluid aliquots (bladder, brain,
GI, heart, lung, liver, spleen, urine, body remains)
were excised, weighed, counted, and the results
adjusted for decay relative to the time of counting.
Biodistribution and pharmacokinetic results were
expressed as percent of actual injected dose per gram
tissue or fluid (%ID/g).

Efficacy of 99mTc-F4A in mice with carotid
thrombus
In vivo targeting of 99mTc-F4A was performed in
mice (male, Harlan, C57BL/6, 4-6 wks) following the
introduction of a carotid thrombus using the Rose
Bengal method. [30, 31] Briefly, mice were
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administered 60 µg/g body weight by tail vein
injection of a 20 mg/mL solution of Rose Bengal dye
(the singlet oxygen was generated by the
photoactivation of the dye). HeNe laser (540 nm, 1.5
mW/cm2) was focused for 45 min to 50 min on a
surgically exposed carotid artery distal to a Doppler
cuff probe until blood flow was decreased at least 70%
relative to baseline. After laser treatment, the mice
were heparinized and 99mTc-F4A (n=4) or an irrelevant
peptide (GGSHPSRPRAG) tetrameric 99mTc-control
(99mTc-I4A, n=4, 3 µCi/g BW, ~75 µCi/mouse). At 2 h,
%ID/g of the thrombotic carotid and its contralateral
control vessel were determined using an automatic
well counter (Wizard 3, Perkin-Elmer). To confirm in
vivo imaging efficacy, an additional secondary cohort
of 5 mice with carotid thrombus created as above
were administered 40 mCi of 99mTc-F4A and imaged
two hours later with a Multispectral FX multimodal
imaging system (Bruker-Biospin, Billerica, MA) with
the isotope phosphor screen for planar scintigraphy
using a 1.0 min acquisition time.

Fibrin targeting in an LVAD mock flow loop
A HMII LVAD controlled by a computer console
was inserted into a 200 mL mock flow loop comprised
of ½” plastic tubing interconnecting a PBS:fresh
heparinized human plasma (1:1) reservoir, an
injection port, a media drainage port, and an inline ½”
plastic chamber. Uniform human fibrin clots aged 24
h were supported within the inline chamber using a
highly porous, single thread layer of cotton gauze.
The LVAD was operated at maximum flow rate
(~10,000 RPM, 6 L/flow per minute). 99mTc-F4A or
99mTc-F1A (0.5 mCi) were injected into the loop and
allowed to circulate for 2 min followed by a 2 min
plasma/PBS wash to remove unbound radioactivity.
Recovered clot radioactivity was counted in a
calibrated gamma well counter and the results
adjusted for decay.

Targeting of thrombus in excised LVADs using
a mock flow loop
HMII excised (n=5) from patients without
clinical suspicion of pump thrombus were rewired for
operation in the heparinized human plasma:PBS (1:1)
mock loop and operated at the preprogrammed
patient controller pump rate of (9400 RPM). 99mTc-F4A
(0.5 mCi) was injected into the loop for 30 min then
washed with fresh circulating plasma/PBS for 2 min.
The pumps were removed from the loop and imaged
with single-photon emission computed tomography
(SPECT) with CT (NanoSPECT/CT, Bioscan, Inc.,
Poway, CA). Helical SPECT and CT scans were
performed with 8 projections per rotation for 5 min
per projection and 65 kVp, 177 µAs, respectively, and
http://www.thno.org
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reconstructed with Invivoscope software. Total
photon counts were calibrated to total radioactivity of
the sample.

Statistical Analysis
Data were analyzed using Student's T-Tests,
paired T-tests, or analysis of variance (SAS Inc., Cary,
NC). Data are presented as the mean ± standard error
of the mean unless otherwise stated. In vivo targeting
of carotid thrombus was a completely randomized
design replicated to allow detection of a 20%
difference with 80% power at an alpha level of 0.05.

Results
99mTc-F1A

and 99mTc-F4A fibrin affinity,
radiolabel stability, plasma interference
The binding affinity, radio-stability, and plasma
matrix effects of the 99mTc-F1A and 99mTc-F4A probes
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were characterized. Titrated dosages of 99mTc-F1A
bound to uniform fibrin clots in PBS with good
affinity (Kd ~10.2 µM), which was consistent with the
earlier report and phage display-derived peptides in
general [26] (Figure 3A). By comparison, 99mTc-F4A
bound with extraordinary affinity and avidity to
analogous fibrin targets in PBS. 99mTc-F4A bound to
each clot was not displaced by unlabeled F1A titrated
to 120,000 molar excess relative to 99mTc-F4A,
reflecting extraordinary avidity (Figure 3B).
Radiolabel stability of 99mTc-F1A and 99mTc-F4A
probes was studied in the presence of excess cysteine,
a strong tridentate ligand. Fibrin clot nuclear signal
measured for 99mTc-F1A or 99mTc-F4A binding in PBS
with or without cysteine did not differ (p>0.05)
(Figure 3C, D). However, the binding of 99mTc-F1A to
fibrin clots in the presence of human plasma was
severely compromised (p<0.05) compared with PBS

Figure 3. A Titrated dosages of 99mTc-F1A bound to uniform fibrin clot in PBS. The dissociation constant (Kd ~10.2 µM) was adjusted for decay and estimated using the Hill
slope model, Y=Bmax*Xh / (Kdh + Xh) three times independently (± s.e.m.). Total fibrin concentration was estimated from plasma fibrinogen (0.735 nmol per clot). B The
percentage of 99mTc-F4A bound to each clot in the presence of unlabeled F1A (monomer) at molar ratios up to 120,000 to 1. 99mTc-F1A (C) and 99mTc-F4A (D) bound to clots
in the presence of PBS and in PBS with excess cysteine to demonstrate 99mTc labelling stability. However, in a 50:50 PBS:human plasma mixture the binding of 99mTc-F1A to clot
was dramatically reduced (p<0.05) whereas 99mTc-F4A was unaffected. E The attenuation of Na99mTcO4 from 20 µCi down to 0.5 µCi by titanium plate (1 mm), equivalent to the
housing of HMII, was 23% ± 3% independent of radioactivity level (n=3/level). HMII: HeartMate II; PBS: phosphate buffered saline.

http://www.thno.org
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alone, indicating a significant matrix effect (Figure
3C). In contradistinction, 99mTc-F4A binding was
unaffected by human plasma: the probe bound
equivalently to the fibrin clots in PBS and in plasma
(p>0.05) (Figure 3D). Of note, a slight increase in
99mTc-F4A fibrin signal was appreciated in the
presence of plasma, which may reflect blockage of
nonspecific binding sites on the plastic well walls,
increasing the bioavailability of the free 99mTc-F4A
probe to interact with the clots.

Nuclear signal attenuation due to titanium
LVAD housing
The decision to approach the LVAD thrombus
diagnosis problem with a nuclear medicine solution
reflected the need for the probe signal to penetrate
through the titanium pump housing. The attenuation
of Na99mTcO4 by a titanium plate of equivalent quality
and thickness (1 mm) to that used to form the housing
for HMII was evaluated by titrating the isotope
concentration from 20 µCi down to 0.5 µCi. Gamma
scintigraphy imaging of the phantoms with and
without the titanium sheet shielding revealed 23% ±
3% nuclear signal attenuation independent of the
level of radioactivity studied (Figure 3E). The
influence of signal attenuation due to the titanium
housing, although present, was relatively minor,
permitting both the high sensitivity and quantitative
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gamma imaging.

Pharmacokinetics (PK) and biodistribution
(BD) of 99mTc-F1A and 99mTc-F4A in mice
The pharmacokinetics (PK) and biodistribution
(BD) of the reference radiolabeled 99mTc-F1A were
compared to that of the 99mTc-F4A in mice in triplicate.
Both agents closely followed a two-compartment
bi-exponential PK model (Figure 4A, B). The alpha
distribution half-life of 99mTc-F4A in mice (5.0 ± 1.9
min) was 41% faster (p<0.05) than that of 99mTc-F1A
(8.6 ± 1.9 min). Similarly, the beta elimination half-life
of 99mTc-F4A (124.7 ± 41.3 min) was 50 min shorter
(28%) than 99mTc-F1A (174.2 ± 26.2 min) (p= 0.08),
which was likely related to the minimal plasma
interactions with 99mTc-F4A.
The organ biodistribution of both agents at the
conclusion of the PK study (180 min) was very similar
with neither probe accumulating substantially in the
lung, liver or spleen. Such low uptake by
reticuloendothelial organs reflects the relatively small
sizes of 99mTc-F1A and 99mTc-F4A. Essentially, all of
the 99mTc activity was excreted through the urinary
system into kidney, bladder or urine at the 3 h
sampling time point (Figure 4C, D). These data
suggest that background circulating 99mTc-F4A blood
pool levels will decrease rapidly without significant
tissue accumulation, minimizing the time between
probe injection and signal readout.

Efficacy of 99mTc-F4A in mice
The

targeted binding of
to carotid thrombus was
robust and occurred in every animal
studied: carotid clot, 16.3 ± 3.3
%ID/g versus contralateral carotid
(no clot), 3.1 ± 1.5 %ID/g, p<0.05
(Figure 5). 99mTc-I4A had poor
carotid clot binding: carotid clot, 3.4
± 1.6 %ID/g versus the contralateral
clot-free carotid, 1.1 ± 0.5 %ID/g,
p<0.05. As expected, 99mTc-F4A (16.3
± 3.3 %ID/g) binding to the injured
carotid was much greater (p<0.05)
than that measured with 99mTc-I4A
(3.4 ± 1.6 % ID/g). These data
99mTc-F4A
corroborate
that
effectively,
specifically,
and
systemically targeted native carotid
thrombus in vivo.
In a separate cohort of mice
bearing carotid thrombus, 99mTc-F4A
was administered by tail vein
injection and mice were imaged
using Multispectral FX multimodal
99mTc-F4A

Figure 4. The pharmacokinetics (PK) and biodistribution (BD) of the reference radiolabeled 99mTc-F1A compared
to 99mTc-F4A in mice (n=3/treatment). A Both agents, presented as percent injected radioactivity per gram blood
(%ID/g), closely followed a two-compartment bi-exponential PK model. B The alpha distribution half-life of
99mTc-F4A in mice (5.0 ± 1.9 min) was 41% faster (p=0.04) than that of 99mTc-F1A (8.6 ± 1.9 min). Similarly, the beta
elimination half-life of 99mTc-F4A (124.7 ± 41.3 min) was 50 min shorter (28%) than that of 99mTc-F1A (174.2 ± 26.2
min) (p= 0.08), which were likely related to minimal plasma interactions with 99mTc-F4A. Mouse organ
biodistribution including body remains (n=3/treatment) of 99mTc-F1A (C) and 99mTc-F4A (D) at the conclusion of
the PK study (180 min) were similar. Neither probe accumulated substantially in the lung, liver or spleen. Virtually
all of the 99mTc activity was excreted through the urinary system (kidney, bladder and urine).

http://www.thno.org
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imaging system (Bruker-Biospin, Billerica, MA) after 2
h. Figure 5B provides a representative in vivo image
showing robust signal (arbitrary units) in the targeted
carotid with negligible contrast in the uninjured
contralateral vessel. These data suggest that the
binding to carotid thrombus occurs relatively soon
after injection of 99mTc-F4A, resulting in strong
contrast greater than the circulating background and
the contralateral artery at 2 h.

Ex vivo LVAD flow study using a mock loop
The high shear and high blood flow (~6 L/min)
of the LVAD required to pump the entire circulating
blood volume of the patient every minute place severe
demands on probe binding affinity and clot retention
of the nuclear probe. Therefore, fibrin clot
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accumulation of the reference probe, 99mTc-F1A, and
99mTc-F4A were compared in triplicate under the
maximal flow and shear conditions produced by a
HMII using a mock loop circulating a
plasma:PBS:heparin mixture (Figure 6B). After 2 min
of circulation, 99mTc-F4A was rapidly bound and
retained on the clot whereas the monomeric reference,
99mTc-F1A, was associated at only negligible levels
(p<0.01) (Figure 6A). The superior binding of
99mTc-F4A to fibrin clots under high flow conditions
illustrated the advantage of the high avidity
PEG-based tetrameric design for increasing fibrin
binding and minimizing nonspecific plasma
interference.

Figure 5. Targeted fibrin binding of 99mTc-F4A to carotid thrombus was compared to an irrelevantly targeted 99mTc-I4A probe (~75 µCi/animal). A The signal from the
clot-bearing carotid (%ID/g) was compared to the clot-free contralateral vessel response. 99mTc-F4A binding to carotid thrombus was much greater than uptake in the clot-free
contralateral carotid vessel (p<0.05). 99mTc-I4A bound poorly to carotid thrombus and nuclear probe uptake did not differ from the nonspecific signal obtained in the clot-free
carotid. Binding of the fibrin-specific 99mTc-F4A to carotid clot was markedly greater (p=0.01) than the nonspecific binding of 99mTc-I4A to thrombus. *p<0.05. B Representative
maximum intensity projection image with a color map (arbitrary units) from 1 of 5 mice administered 99mTc-F4A (40 µCi) by tail vein injection then imaged 2 h later with a
Multispectral FX multimodal imaging system (Bruker-Biospin, Billerica, MA). A Marked single source signal originating from the right carotid thrombus was noted. All animals
(n=5) displayed a strong in vivo carotid nuclear signal following 99mTc-F4A.

Figure 6. A HMII mock flow loop design: circulation media was 200 mL of heparinized 50:50 plasma:PBS. Activity injected for each probe was 0.5 mCi. B Average percent
radioactivity (± s.e.m.) of 99mTc-F4A versus 99mTc-F1A bound to uniform fibrin clots after 2 min of circulation in HMII mock flow loop. *p<0.05, n=3/treatment group, HMII:
HeartMate II
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Figure 7. 99mTc-F4A signal was assessed for the inlet cannula (metallic and Dacron® segments), the inlet stator/bearing, turbine, outlet bearing, and outlet cannula regions. Strong
99mTc-F4A signals were noted in the metallic and Dacron® inlet cannula segments in A and in the flexible, Dacron® segment in panel B. Prominent 99mTc-F4A signal was observed
around the inlet bearing in C and both the inlet and outlet bearings/stator in D. Fibrin accumulation coating the walls of the outlet cannulas were frequently noted as in E. This
LVAD was notable also for thrombus associated with the inlet and outlet bearings. Yellow arrows in each image point to regions of 99mTc-F4A signal corresponding to fibrin
deposition and accumulation. Abbreviated clinical histories: A Implanted 520 days. Early hemolysis after implantation. Peak LDH 1300 U/L. Resolved with eptifibatide and
bivalrudin. B Implanted 830 days. No hemolysis. Routine transplant. C Implanted 146 days. Hemolysis noted with a peak LDH 800 U/L. Negative ramp study. LDH trended
downward and the heart was transplanted soon thereafter. D Implanted 410 days. Sustained hemolysis with a LDH peak 3400 U/L. Pump exchanged for suspected pump
thrombosis. E Ischemic stroke 7 days after implantation. No hemolysis. Pump exchanged. LVAD: left ventricular assist device; LDH: lactic dehydrogenase.

Assessments of thrombus in explanted rewired
LVADs in a mock loop with 99mTc-F4A
For further proof of concept of this clot-binding
contrast agent, 99mTc-F4A binding was assessed in
explanted LVADs from patients (examples of 5 from
over 60 pumps evaluated are shown) receiving heart
transplants or surgical pump exchange to
demonstrate the imaging agent affinity for the native
intra-pump fibrin deposition and to determine if high
resolution imaging could spatially characterize the
extent of thrombus formation (Figure 7). 99mTc-F4A
signal was assessed for the inlet cannula (metallic and
Dacron® graft segments), the inlet stator/bearing,
turbine, outlet bearing, and outlet cannula regions.
Strong 99mTc-F4A signals were noted in the metallic
and Dacron® inlet cannula segments in Figure 7A and
in the flexible, Dacron® segment in Figure 7B.
Prominent 99mTc-F4A signal around the inlet bearing
in Figure 7C and both the inlet and outlet
bearings/stator in Figure 7D were also observed.
Fibrin accumulation coating the walls of the outlet
cannulas was frequently noted as in Figure 7E. The
occasional LVAD had no detectable 99mTc-F4A, but
the prevalence of HMII pumps with detectable fibrin
using a nanoSPECT/CT imaging was high in an
initial cohort (17/18). Inherent nonspecific binding of
99mTc-F4A to the LVAD pump was nondetectable
(Figure S1). Additionally, six pumps were submitted
to the vendor for independent pathologic evaluation
and corroborated the nuclear imaging results
(Figure S2).

Discussion
Detection and characterization of LVAD
thrombus is an unmet medical need with significant
clinical importance in the heart failure community not
only for diagnosing pump thrombosis but for better
individualizing anticoagulation regimens. 99mTc-F4A
is a prototype tetrameric nuclear probe capable of
binding fibrin deposits in the high-shear high-flow
chambers within LVADs and is detectable through
the titanium pump housings. Four bifunctional
monomeric probes (99mTc-F1A) were connected
through a tetrameric polyethylene glycol core to form
99mTc-F4A. In addition to overcoming high shear, this
prototype probe effectively targeted aged thrombus
exposed long-term to anticoagulation, which virtually
all fibrin-specific contrast agents have failed to target
to date [22].
As shown, 99mTc-F4A had extraordinary binding
avidity to fibrin clots that could not be displaced in
vitro by the F1A monomeric probe at ratios up to
120,000:1 molar excess. Moreover, in the LVAD ex
vivo mock flow loop, the binding affinity of 99mTc-F1A
to fibrin clots was less than 99mTc-F4A. The
bifunctional monomeric 99mTc-F1A and the tetrameric
99mTc-F4A share the same cyclic peptide ligand and
99mTc chelating strategy. While the monomeric probe
can associate with a single fibrin fibril, the tetrameric
PEG arms allow the 99mTc-F4A probe to interact with
multiple fibrin fibrils or to bind around a single fibril
at multiple sites. Hypotheses based on possible 3
dimensional conformations will be complex to resolve
but fascinating avenues for future study.
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Hydrophobic peptide binding to plasma protein
constituents is common among peptide-based probes
in general, and was observed for 99mTc-F1A in the
present study as plasma interference with binding in
vitro. While the reported specific binding to plasma
proteins such as albumin may be low on a micromolar
basis, the concentrations of albumin and other plasma
proteins in blood are very high (up to 3-4 g/dL). This
large capacity of plasma proteins for nonspecific
adsorption requires increased probe dosages for
targeting purposes and can result in elevated
persistent background signal, reducing detection
sensitivity for critical small thrombin deposits
associated with HMII pump bearings.
Indeed, almost all thrombus probes reported to
date bind or accumulate in acute clots, typically less
than 72 h, with poorer binding achieved as the
thrombus ages and accessible fibrin content decreases.
As an example, a recent promising fibrin-binding
peptide (FBP8)-PET probe was reported to have
efficacy towards acute thrombus, which then
diminished quickly as the clot aged. This loss of fibrin
binding paralleled a reduction in fibrin content as the
clot organized [32, 33]. LVADs presented in this study
were obtained from patients 7 to 830 days following
implantation. In all instances, the thrombus was an
acellular almost pure fibrin accretion. In published
reports of severe cases, the intra-pump thrombus
deposits had a "woody" layered appearance
resembling growth rings in a tree trunk [34].
Anticoagulation with warfarin and aspirin is
prescribed chronically to diminish the incidence of
thrombosis in LVADs. However, with exception of
99mTc-NC100668, which employed a partial peptide
[35-37],
analogue
of
alpha2-antiplasmin
thrombus-specific contrast agents have routinely
failed to be effective in the presence of anticoagulation
[22]. In the present study, 99mTc-F4A was effective
against aged fibrin deposits in LVADs exposed to
anticoagulation during patient use and during ex vivo
evaluation in the mock-flow loops.
Given the continued high bleeding and stroke
rates associated with LVADs despite close
management
under
current
guidelines
for
anticoagulation management, 99mTc-F4A may offer a
key tool to individualize anticoagulation goals for
patients, improving management decisions that
minimize GIB and strokes. Although fibrin deposits
were noted in the outlet and inlet cannulas and
bearings and occasionally along the axial rotor, the
clinical relevance of thrombus accumulation in one
pump region versus another remains to be fully
resolved. LDH is often used as a surrogate clinical
marker of pump thrombosis, particularly for very late
conditions, but the early correlation between transient
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spikes in LDH and significant pump thrombosis is
uncertain. Similarly, the correlation between LVAD
operational voltage variations and spikes alone have
not been reliable enough to warrant major clinical
decisions, such as pump exchanges, and the
relationship between voltage variation and transient
pump thrombosis events remains unclear. 99mTc-F4A
is anticipated to provide a robust metric to assess
accumulation in LVAD thrombus to help individually
tune anticoagulation (INR) targets to minimize stroke
and bleeding risk. Periodic testing, particularly in
response to clinical status triggers, could be used to
affirm or adjust the clinical management plan over
time.
99mTc-F4A was developed with a previously
characterized fibrin peptide analogue to test the
concept of a tetrameric PEG cross-linked bifunctional
probe as a means to overcome the LVAD challenges of
aged clot, chronic anticoagulation, and high shear
blood flow. While the potential success of this probe is
supported by the data presented, chemistry
improvements as well as further characterization are
required. From a chemistry perspective, 99mTc-F4A
utilized a commercially available tetrameric PEG core
with unexpectedly high variability with regard to
PEG arm lengths. This variability complicated
analytically-supported process scale-up efforts
required to conduct additional analytical, in vitro, and
in vivo characterization studies. The next generation
of probe(s) will require scalable synthesis of the
tetrameric PEG including highly controlled individual
PEG arm lengths. Additionally, while the present
prototype probe was synthesized using solid phase
chemistry, the scaled version of 99mTc-F4A will likely
require the adoption of a solution phase method.
Improvements in process and characterization will
better support large animal LVAD homing studies
and improved pharmacokinetic assessments, with
high clinical translation relevance.
In summary, 99mTc-F4A is a prototype probe
incorporating a tetrameric PEG core found to achieve
high avidity against aged fibrin with minimal plasma
matrix interference for direct noninvasive LVAD
thrombus assessments. 99mTc-F4A targeted fibrin
effectively in vivo in mice as well as ex vivo in human
excised LVADs rewired and operated in a mock-loop.
Biodistribution studies demonstrated that the
unbound probe cleared rapidly through the urinary
system with negligible liver, spleen, or lung
accumulation. 99mTc-F4A detected and spatially
characterized thrombus in operational LVADs excised
from patients with and without prior suspicion of
pump thrombus. 99mTc-F4A could be applied to
investigate biomarkers or clinical symptoms
suggestive of pump thrombus formation as well as
http://www.thno.org
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better individualize anticoagulation management to
minimize bleeding while reducing thrombotic
complications and pump exchanges.

assessments of LVAD thrombus consistent with a
global device inspection protocol for returned pumps
from any institution.
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